Guardant Health (NASDAQ:GH – Get Free Report) and Adicet Bio (NASDAQ:ACET – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Profitability
This table compares Guardant Health and Adicet Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Guardant Health | -40.10% | N/A | -26.42% |
| Adicet Bio | N/A | -80.35% | -65.44% |
Earnings and Valuation
This table compares Guardant Health and Adicet Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Guardant Health | $982.02 million | 17.15 | -$416.28 million | ($3.39) | -37.47 |
| Adicet Bio | N/A | N/A | -$116.80 million | ($14.90) | -0.53 |
Adicet Bio has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Guardant Health and Adicet Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Guardant Health | 1 | 0 | 19 | 1 | 2.95 |
| Adicet Bio | 1 | 1 | 5 | 1 | 2.75 |
Guardant Health currently has a consensus price target of $136.37, suggesting a potential upside of 7.35%. Adicet Bio has a consensus price target of $48.80, suggesting a potential upside of 523.24%. Given Adicet Bio’s higher probable upside, analysts plainly believe Adicet Bio is more favorable than Guardant Health.
Institutional and Insider Ownership
92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by company insiders. Comparatively, 3.4% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Guardant Health has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.
Summary
Guardant Health beats Adicet Bio on 9 of the 13 factors compared between the two stocks.
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
About Adicet Bio
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
